Company Overview - ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS, and oncology/hematology [1] - The company has an active pipeline of six drugs and one medical device under development, utilizing inlicensed technology from renowned research institutions [5] Product Development - ABVC's ABV-1504, containing the active pharmaceutical ingredient Radix Polygala (PDC-1421), aims to address the gap left by the discontinuation of Prozac, particularly in treating Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD) [1][3] - PDC-1421 has completed Phase II clinical trials and is progressing towards Phase III trials globally, with patents approved in the USA and other countries valid until 2041 [1] Market Opportunity - The global MDD market is projected to grow from 14.96 billion by 2032, with a CAGR of 2.8% [4] - The global ADHD treatment market is expected to increase from 163 million in 2021, is forecasted to grow at a CAGR of 39% through 2030, reaching $3.2 billion [4] Competitive Advantage - ABV-1504 is positioned as a safer and more effective alternative to traditional antidepressants like Prozac, with a favorable safety profile and fewer side effects [3] - Internal studies indicate that PDC-1421 achieved a MADRS score reduction of -13.21 from baseline over 6 weeks, with a placebo-subtracted difference of -4.1, demonstrating significant efficacy in treating MDD [3]
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21